Targeting VEGF ligands and receptors in cancer

Drug Discovery Today: TARGETS

Volumn 2, Issue 2, 2003, Pages 48-57

  Malik, Ajay K ^a   Gerber, Hans Peter ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (8 HYDROXY 6 METHOXY 1 OXO 1H 2 BENZOPYRAN 3 YL)PROPIONIC ACID; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; 4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; 5,6,7,13 TETRAHYDRO 12 (3 HYDROXYPROPYL) 9 ISOPROPOXYMETHYLINDENO[2,1 A]PYRROLO[3,4 C]CARBAZOL 5(12H) ONE DIMETHYLGLYCINE ESTER; AE 941; ANGIOGENESIS INHIBITOR; ANGIOZYME; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTISENSE OLIGONUCLEOTIDE; BEVACIZUMAB; CISPLATIN; FLUOROURACIL; GEMCITABINE; LIPOSOME; MONOCLONAL ANTIBODY 2C3; MONOCLONAL ANTIBODY C11; MONOCLONAL ANTIBODY MF1; MONOCLONAL ANTIBODY MV833; PEGAPTANIB; PROTEIN TYROSINE KINASE INHIBITOR; RIBOZYME; SEMAXANIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR; VATALANIB;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ATAXIA; AUTOCRINE EFFECT; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN HEMORRHAGE; BREAST CANCER; CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG SPECIFICITY; DRUG TARGETING; DYSPNEA; EFFECTOR CELL; FATIGUE; GENE EXPRESSION; HEADACHE; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HUMAN; HYPERTENSION; ISCHEMIA; KAPOSI SARCOMA; KIDNEY CARCINOMA; KIDNEY DYSFUNCTION; LONG TERM CARE; LUNG EMBOLISM; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MELANOMA; MULTIPLE MYELOMA; MYELODYSPLASIA; MYELOMA; NAUSEA; NEUTROPENIA; NONHUMAN; PANCREAS CANCER; PARACRINE SIGNALING; PATIENT SELECTION; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN TARGETING; PROTEINURIA; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SOLID TUMOR; SOMNOLENCE; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; VOMITING;

EID: 0347325027     PISSN: 17418372     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1477-3627(03)02292-x     Document Type: Review

References (85)

1. Lewis, W.H. (1927) The vascular pattern of tumors. Johns Hopkins Hosp. Bull. 41, 156-162
2. Hanahan, D. et al. (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353-364
3. Ferrara, N. (1999) Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int. 56, 794-814
4. Brown, L. et al. (1992) Vascular permeability factor mRNA and protein expression in human kidney. Kidney Int. 42, 1457-1461
5. Kasahara, Y. et al. (2000) Inhibition of VEGF receptors cases lung cell apoptosis and emphysema. J. Clin. Invest. 106, 1311-1319
6. Ferrara, N. (2001) Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am. J. Physiol. Cell Physiol. 280, C1358-C1366
7. Gerber, H.P. et al. (2002) VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 417, 954-958
8. Ferrara, N. et al. (1997) The biology of vascular endothelial growth factor. Endocr. Rev. 18, 4-25
9. Hidaka, M. et al. (1999) Conditional requirement for the Flk-1 receptor in the in vitro generation of early hematopoietic cells. Proc. Natl. Acad. Sci. U. S. A. 96, 7370-7375
10. Gerber, H. et al. (2003) The role of VEGF in normal and neoplastic hematopoiesis. J. Mol. Med. 81, 20-31
11. Hattori, K. et al. (2002) Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat. Med. 8, 841-849
12. Poon, R.T-P. et al. (2001) Clinical implications of circulating angiogenic factors in cancer patients. J. Clin. Oncol. 19, 1207-1225
13. Bellamy, W.T. et al. (1999) Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res. 59, 728-733
14. Fiedler, W. et al. (1997) Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 89, 1870-1875
15. Bellamy, W.T. et al. (2001) Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukaemia progenitor formation in myelodysplastic syndromes. Blood 97, 1427-1434
16. Dias, S. et al. (2000) Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J. Clin. Invest. 106, 511-521
17. Zhu, Z. et al. (2002) Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics. Curr. Cancer Drug Targets 2, 135-156
18. Cascinu, S. et al. (2000) Differences of vascular endothelial growth factor (VEGF) expression between liver and abdominal metastases from colon cancer. Implications for the treatment with VEGF inhibitors. Clin. Exp. Metastasis 18, 651-655
19. Lyden, D. et al. (2001) Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 7, 1194-1201
20. Christofferson, R.E. et al. (1995) Ribozymes as human therapeutic agents. J. Med. Chem. 38, 2023-2037
21. Kijima, H. et al. (1995) Therapeutic applications of ribozymes. Pharmacol. Ther. 68, 247-268
22. Kerbel, R.S. (2001) Clinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results. J. Clin. Oncol. 19 (Suppl. 18), 45S-51S
23. Kerbel, R. et al. (2002) Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer 2, 727-739
24. Miller, K.D. et al. (2001) Redefining the target: chemotherapeutics as antiangiogenics. J. Clin. Oncol. 19, 1195-1206
25. Jain, R.K. (2001) Normalizing tumor vasculature with antiangiogenic therapy: a new paradigm for combination therapy. Nat. Med. 7, 987-989
26. Relf, M. et al. (1997) Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 57, 963-969
27. Chen, Y. et al. (1999) Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J. Mol. Biol. 293, 865-881
28. Presta, L.G. et al. (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57, 4593-4599
29. Yang, J. et al. (2002) A randomized double-blind placebo-controlled trial of bevacizumab (anti-VEGF antibody) demonstrating a prolongation in time to progression in patients with metastatic renal cell cancer. Proc. Am. Soc. Clin. Oncol. 21, 5a
30. Burstein, H. et al. (2002) Phase II trial of the anti-VEGF antibody bevacizurnab in combination with vinorelbine for refractory advanced breast cancer. Breast Cancer Res. Treat. 76 (Suppl. 1), S11
31. Miller, K. et al. (2002) Phase II trial of capecitabine (Xeloda®) plus bevacizumab (Avastin™) versus capecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane. Breast Cancer Res. Treat. 76 (Suppl. 1), S37
32. Bergsland, E. et al. (2001) Bevacizumab (BV) + chemotherapy (CT) may improve survival in metastatic colorectal cancer (MCRC) subjects with unfavorable prognostic indicators. Proc. Am. Soc. Clin. Oncol. 20, 124b
33. DeVore, R. et al. (2000) A random ized phase II trial comparing rhuMab VEGF (recombinant humanized monoclonal antibody to vascular endothelial growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage III/IV NSCLC. Proc. Am. Soc. Clin. Oncol. 19, 485a
34. Langmuir, V.K. et al. (2002) Successful long-term therapy with bevacizumab (Avastin) in solid tumors. Proc. Am. Soc. Clin. Oncol. 21, 9a
35. Gordon, M.S. et al. (2001) Phase 1 safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. 19, 843-850
36. Henry, T.D. et al. (2001) Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease. Am. Heart J. 142, 872-880
37. Shen, B.Q. et al. (1999) Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase C signaling pathway. J. Biol. Chem. 274, 33057-33063
38. Granger, J.P. et al. (2000) Abnormal pressure-natriuresis in hypertension: role of nitric oxide. Aceta Physiol. Scand. 168, 161-168
39. 165 mediates glomerular endothelial repair. J. Clin. Invest. 104, 913-923
40. Kanai, T. et al. (1998) Anti-tumor and anti-metastatic effects of human-vascular-eudothelial-growth-factor-neutralizing antibody on human colon and gastric carcinoma xenotransplanted orthotopically into nude mice. Int. J. Cancer 77, 933-936
41. Brekken, R.A. et al. (2000) Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1 by a monoclonal anti-VEGF antibody blocks tumour growth in mice. Cancer Res. 60, 5117-5124
42. Posey, J. et al. (2002) A phase I trial of an anti-KDR (VEGFR) chimeric antibody in patients with liver metastases in colorectal cancer (CRC). Proc. Am. Soc. Clin. Oncol. 21, 17a
43. Smolich, B.D. et al. (2001) The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood 97, 1413-1421
44. Raymond, E. et al. (2002) First results of a phase I and pharmacokinetic study of SUØ11248, a novel oral anti-angiogenic agent, in patients with advanced solid tumours. Eur. J. Cancer 38 (Suppl. 7), S17
45. Hurwitz, H. et al. (2002) Clinical evaluation of ZD6474, an orally active inhibitor of VEGF signaling, in patients with solid tumors. Proc. Am. Soc. Clin. Oncol. 21, 82a
46. Fong, T.A. et al. (1999) SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumour vascularization, and growth of multiple tumour types. Cancer Res. 59, 99-106
47. Ono, M. et al. (2000) SU5416 inhibits the tyrosine kinase vascular endothelial growth factor receptor FLT-1 in vivo. Proc. Annu. Meet. Am. Assoc. Cancer Res. 41, 1-5
48. Laird, A.D. et al. (2000) SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res. 60, 4152-4160
49. Strawn, L.M. et al (1996) Flk-1 as a target for tumor growth inhibition. Cancer Res. 56, 3540-3545
50. Shaheen, R.M. et al. (2001) Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms. Cancer Res. 61, 1464-1468
51. Arasteh, K. et al. (1999) A multicenter, dose-escalating study in patients with AIDS-related Kaposi's sarcoma. Clin. Cancer Res. 5, 3731s
52. Aiello, L.P. et al. (2002) Rapid and durable recovery of visual function in a patient with von Hippel-Lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor SU5416. Ophthalmology 109, 1745-1751
53. Mesters, R.M. et al. (2001) Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. Blood 98, 241-243
54. Anonymous (2002) Pharmacia's SU5416 not effective. Expert Rev. Anticancer Ther. 2, 5
55. Richard, S. et al. (2002) Paradoxical secondary polycythemia in von Hippel-Lindau patients treated with anti-vascular endothelial growth factor receptor therapy. Blood 99, 3851-3853
56. Grasselli, G. et al. (2002) Dose-escalation and pharmacologic study of oral SU-006668 in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. 21, 18a
57. Kuenen, B. et al. (2002) Dose finding study of SU6668 given thrice daily by oral route under fed conditions in patients with advanced malignancies. Proc. Am. Soc. Clin. Oncol. 21, p110a
58. Brahmer, J.R. et al. (2002) A phase I study of SU6668 in patients with refractory solid tumors. Proc. Am. Soc. Clin. Oncol. 21, 84
59. Morimoto, A. et al. (2002) Biomarker analysis of patient samples from a phase I clinical trial using the angiogenesis inhibitor, SU6668, for treatment of advanced solid tumors. Proc. Am. Soc. Clin. Oncol. 21, p85a
60. Britten, C.D. et al. (2002) Phase 1 trial of SU6668, a small molecule receptor tyrosine kinase inhibitor, given twice daily in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol. 21, 28b
61. Wedge, S. et al. (2002) ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 62, 4645-4655
62. Wood, J.M. et al. (2000) PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor induced responses and tumor growth after oral administration. Cancer Res. 60, 2178-2189
63. Drevs, J. et al. (2001) A phase 1 dose-escalating and pharmacokinetic (PK) study of the VEGF-receptor-inhibitor PTK787/ZK222584 (PTK/ZK) in patients with liver metastasis of advanced cancer. Proc. Am. Soc. Clin. Oncol. 20, 100a
64. Drevs, J. et al. (2002) Surrogate markers for the assessment of biological activity of the VEGF-receptor inhibitor PTK787/ZK 222584 (PTK/ZK) in two clinical phase I trials. Proc. Am. Soc. Clin. Oncol. 21, 85a
65. Roboz, G.J. et al. (2002) Phase I trial of PTK787/ZK 222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, in acute myeloid leukemia and myelodysplastic syndrome. Blood 100, 11
66. Lin, B. et al. (2002) The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 62, 5019-5026
67. Roberts, W.G. et al. (2002) Preclinical development of CP-547,632, a novel VEGFR-2 inhibitor for cancer therapy. Proc. Am. Soc. Clin. Oncol. 21, p119a
68. Karp, D.D. et al. (2002) Preliminary pharmacokinetic (PK) characteristics of an oral vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor (TKI), CP-547,632 in patients (pts) with advanced solid tumors. Proc. Am. Assoc. Cancer Res. 43, 554
69. Tolcher, A.W. et al. (2002) A phase I and biologic correlative study of an oral vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, CP-547, 632, in patients (pts) with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. 20, 84a
70. Gingras, D. et al. (2001) AE-941 (Neovastat): a novel multifunctional antiangiogenic compound. Expert Rev. Anticancer Ther. 1, 341-347
71. Escudier, B. et al. (2001) AE-941 (Neovastat) shows an excellent safety profile and apears beneficial in patients with solid tumors: rationale for the initiation of 2 phase III clinical trials. Proc. Annu. Meet. Am. Assoc. Cancer Res. 42, 1
72. Batist, G. et al. (2002) Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels. Ann. Oncol. 13, 1259-1263
73. Usman N. et al. (2002) A Phase II Study of angiozyme in Combination with 5-Fluorouracil, Leucovorin and Irinotecan in the treatment of metastatic colorectal cancer patients. AACA NCI EORTC Mol Targets Cancer Ther, 19-22 November
74. Weng, D.E. et al. (2001) Angiozyme pharmacokinetic and safety results: a phase I/II study in patients with refractory solid tumors. Proc. Am. Soc. Clin. Oncol. 21, 99a
75. Sandberg, J.A. et al. (2000) Pharmacokinetics and tolerability of an antiangiogenic ribozyme (ANGIOZYME) in healthy volunteers. J. Clin. Pharmacol. 40, 1462-1469
76. Huang, J. et al. (2001) Highly specific antiangiogenic therapy is effective in suppressing growth of experimental Wilms tumors. J. Pediatr. Surg. 36, 357-361
77. The Eyetech Study Group (2002) Retina 22, 143-152
78. Holash, J. et al. (2002) VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. U. S. A. 99, 11393-11398
79. Dupont, J. et al. (2002) A phase I study of the novel high affinity VEGF blocker VEGF trap in patients with refractory solid tumors and lymphoma. AACR NCI EORTC Mol Targets Cancer Ther, 19-22 November
80. Agata, N. et al. (2001) NM-3, a novel angiogenesis inhibitor, inhibits tumor growth alone and in combination with cyclophosphamide. Proc. Am. Soc. Clin. Oncol. 20, 1
81. Soulie, P. et al. (2002) Phase I and pharmacokinetic study of NM-3 administered orally each day for 21 days every 28 days to patients with advanced solid tumors. Proc. Am. Assoc. Cancer Res. 43, 554
82. Mallamo, J.P. et al. (2002) Identification, SAR and preclinical development of a novel inhibitor of VEGF-dependent angiogenesis. CEP-7055 ACS 223rd, Orlando
83. Jones-Bolin, S. et al. (2002) The effects of the orally-active VEGF-R kinase inhibitor, CEP-7055, on primary tumor growth and metastatic profile in orthotopic models of human pancreatic ductal carcinoma and murine renal carcinoma (RENCA) in mice. Proc. Ann. Meet Am. Assoc. Cancer Res. 43, 1
84. Marx, J. (2002) Obstacle for promising cancer therapy. Science 295, 1444
85. Yu, J.L. et al. (2002) Effect of p53 status on tum or response to antiangiogenic therapy. Science 295, 1526-1528